# A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

> **NCT01144351** · PHASE1 · TERMINATED · sponsor: **Elan Pharmaceuticals** · enrollment: 32 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** ELND002
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01144351
- **Lead sponsor:** Elan Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-03
- **Primary completion:** 2012-12
- **Final completion:** —
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2015-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01144351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01144351, "A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01144351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*